Opdivo + low-dose Yervoy in CheckMate -9LA trial, for the first-line treatment of advanced non-small cell lung cancer met its primary endpoint of superior overall survival .- BMS

-Bristol-Myers Squibb Company announced that CheckMate -9LA, a pivotal Phase III trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) given concomitantly with two cycles of chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC), met its primary endpoint of superior overall survival (OS) at a pre-specified interim analysis. The comparator in this study was chemotherapy alone for up to four cycles followed by optional maintenance therapy. The safety profile of Opdivo plus low-dose Yervoy and two cycles of chemotherapy in CheckMate -9LA was reflective of the known safety profiles of the immunotherapy and chemotherapy components in first-line NSCLC. The company will complete a full evaluation of the CheckMate -9LA data and looks forward to presenting these results at an upcoming congress and sharing them with regulatory authorities.